Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 41Glioma 10Brain Neoplasms 9Gliosarcoma 8Astrocytoma 7Neuroblastoma 6Small Cell Lung Carcinoma 4Oligodendroglioma 4Neoplasms 4Medulloblastoma 4Sarcoma, Ewing 3Sarcoma 3Melanoma 3Somatostatinoma 2Rhabdomyosarcoma 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Neuroendocrine Tumors 2Lung Neoplasms 2Ependymoma 2Diffuse Intrinsic Pontine Glioma 2Desmoplastic Small Round Cell Tumor 2Central Nervous System Neoplasms 2Carcinoma, Neuroendocrine 2Adenoma, Islet Cell 2Supratentorial Neoplasms 1Spinal Cord Neoplasms 1Rhabdoid Tumor 1Prostatic Neoplasms 1

Interventions

abemaciclib 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Spinal Cord Neoplasms × Temozolomide × Clear all
NCT06413706 2026-05-22

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

Eli Lilly and Company

Phase 2 Active not recruiting
45 enrolled
CNS

Brain Neoplasms, Glioma, Neoplasms, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡